NCT05307705
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: PI3K
Breast Cancer Tissue:
Recruitment Status: Recruiting
Phase 1
Drug Category: Serine-Threonine Kinase Inhibitor, Endocrine (Hormone) Therapy, Chemotherapy
Key Eligibility Criteria:
Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases:
Additional Notes: Patients must have solid tumor with the presence of a PIK3CA H1047R mutation
Exclusions: Patients with known or suspected history of untreated or uncontrolled central nervous system (CNS) involvement; Patients with prior exposure to PI3K/AKT/mTOR inhibitor(s) – see trial for details
https://ClinicalTrials.gov/show/NCT05307705